Marvel Biosciences Partners With CMAX for MB-204 Phase I Trial

Bitget2026/10/19 10:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Marvel Biosciences selected CMAX as the Phase I clinical trial site for MB-204, advancing preparations for first-in-human testing.
CMAX and Novotech will serve as clinical partners for the trial.
The initial single ascending dose study will evaluate safety, tolerability and pharmacokinetics to inform a subsequent multiple ascending dose study.
Trial initiation remains subject to regulatory and ethics approvals, along with completion of clinical preparations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marvel Biosciences Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190645PRIMZONEFULLFEED9847588) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Marvel Biosciences Partners With CMAX for MB-204 Phase I Trial

You may also like

Crypto prices